Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ki67-tailored neoadjuvant therapy in luminal breast cancer
NL-OMON54665Phase 2Active, not recruiting
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Jun 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ribociclib, letrozole, doxorubicin, cyclophosphamide and paclitaxel in breast cancer (3 arms), sponsored by Borstkanker Onderzoek Groep. Started Jun 2018; status: active, not recruiting.
02
Drugs
ribociclibletrozoledoxorubicincyclophosphamidepaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON54665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54665.